Kymera Investor Day Presentation Deck

Exponential Clinical Pipeline Growth of Degraders C Existing Modalities TTTTTTT Therapeutic Modality Small molecule inhibitor Antibody Drugs FDA Approved >2000 >100 ~10 ~5 ~4 ~3 ASO Cell Therapy Gene Therapy RNAi Gene editing KYMERA ©2021 KYMERA THERAPEUTICS, INC. Targeted Protein Degradation Drugs FDA Approved 4 ● ● Degraders 2010 Drugs in Clinical Development >15 2020 Elucidation of MOA of thalidomide circa 2010 has profoundly accelerated TPD Clinical programs with protein degraders have grown exponentially in the past 12 months KYMERA R&D DAY - December 16th, 2021 This growth will continue in foreseeable future 2030 PAGE 7

View entire presentation